Treatment of Hypertension With Adalat® in Combination With Other Drugs

Bayer4,497 enrolled

Overview

To investigate the therapeutic effectiveness of long acting nifedipine containing combination therapy in the treatment of hypertensive patients.

Study Type

OBSERVATIONAL

Enrollment

4,497

Conditions

Hypertension

Interventions

Nifedipine (Adalat, BAYA1040)DRUG

Previously untreated hypertensive adult patients starting with combination therapy containing nifedipine or insufficiently controlled hypertensive patients receiving nifedipine as an add-on to existing non-CCB containing antihypertensive therapy. The decision of including the patient as well as decision on dosage and duration is taken by the investigator.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Previously untreated hypertensive patients starting with combination therapy containing nifedipine or * Insufficiently controlled hypertensive pts. receiving nifedipine as an add-on to existing non-CCB (calcium-channel-blocker) containing antihypertensive therapy Exclusion Criteria: * None. Exclusion criteria are defined by contraindications and precautions as stated in the local product information.

Locations (11)

Unnamed facility

Many Locations, Bahrain

Unnamed facility

Many Locations, Egypt

Unnamed facility

Many Locations, Jordan

Unnamed facility

Many Locations, Lebanon

Outcomes

Primary Outcomes

Evaluation of treatment success (lowering of blood pressure in mmHg) in adult hypertensive patients

Time frame: After three months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.